JP2001342147A - Method for preventing johne's disease infection by m-cell uptake control and vaccine therefor - Google Patents
Method for preventing johne's disease infection by m-cell uptake control and vaccine thereforInfo
- Publication number
- JP2001342147A JP2001342147A JP2000163840A JP2000163840A JP2001342147A JP 2001342147 A JP2001342147 A JP 2001342147A JP 2000163840 A JP2000163840 A JP 2000163840A JP 2000163840 A JP2000163840 A JP 2000163840A JP 2001342147 A JP2001342147 A JP 2001342147A
- Authority
- JP
- Japan
- Prior art keywords
- paratuberculosis
- johne
- disease
- infection
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 59
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 29
- 229960005486 vaccine Drugs 0.000 title claims abstract description 15
- 210000003126 m-cell Anatomy 0.000 title abstract description 5
- 244000309466 calf Species 0.000 claims abstract description 34
- 235000021277 colostrum Nutrition 0.000 claims abstract description 21
- 210000003022 colostrum Anatomy 0.000 claims abstract description 21
- 208000026681 Paratuberculosis Diseases 0.000 claims abstract description 20
- 230000009545 invasion Effects 0.000 claims abstract description 19
- 241000186367 Mycobacterium avium Species 0.000 claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 210000004347 intestinal mucosa Anatomy 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 42
- 241000283690 Bos taurus Species 0.000 claims description 27
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 26
- 201000008827 tuberculosis Diseases 0.000 claims description 25
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 20
- 235000013336 milk Nutrition 0.000 abstract description 9
- 210000004080 milk Anatomy 0.000 abstract description 9
- 239000008267 milk Substances 0.000 abstract description 9
- 241000282849 Ruminantia Species 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 40
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 22
- 210000001986 peyer's patch Anatomy 0.000 description 22
- 230000000968 intestinal effect Effects 0.000 description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 241000233866 Fungi Species 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 210000003405 ileum Anatomy 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 241000304886 Bacilli Species 0.000 description 5
- 229930183781 Mycobactin Natural products 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XZGYBQIQSLSHDH-COEJQBHMSA-N mycobactin Chemical compound C1CCCN(O)C(=O)C1NC(=O)C(C)C(CC)OC(=O)C(CCCCN(O)C(=O)\C=C/CCCCCCCCCCCCCCC)NC(=O)C(N=1)COC=1C1=C(C)C=CC=C1O XZGYBQIQSLSHDH-COEJQBHMSA-N 0.000 description 5
- 230000032696 parturition Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 229940126578 oral vaccine Drugs 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 3
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000123208 Fistulina hepatica Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000981595 Zoysia japonica Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 241001506930 atypical mycobacterium Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007727 cost benefit analysis Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 229940108890 emend Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 244000078673 foodborn pathogen Species 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012333 histopathological diagnosis Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- -1 iron ion Chemical class 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 150000002703 mannose derivatives Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、新生動物、特に子
牛のヨーネ病感染を予防するための方法およびヨーネ病
感染予防ワクチンに関する。The present invention relates to a method for preventing neonatal animal infection, particularly calf calf infection, and a vaccine for preventing infection with Johne's disease.
【0002】[0002]
【従来の技術】ヨーネ病は、抗酸菌の一種であるヨーネ
菌に起因する慢性肉芽腫性下痢性伝染病である。我が国
の牛群におけるヨーネ病汚染については、1980年以降、
その発生頭数及び発生地共に拡大傾向にある。すなわ
ち、1990年代より100〜200頭/年の発生があ
り、1999年には800頭を越えている。2. Description of the Related Art Johne's disease is a chronic granulomatous diarrheal infectious disease caused by Mycobacterium tuberculosis, a kind of acid-fast bacterium. Regarding Johne's disease contamination in cattle herds in Japan, since 1980,
Both the number and location of the outbreaks are increasing. That is, there have been 100-200 outbreaks per year since the 1990s, and in 1999 over 800 cases.
【0003】ヨーネ病は出生後、早期に子牛が経口的に
ヨーネ菌に感染することで成立するが、ヨーネ病の感染
から発症までのプロセスは、未だ不明の部分が多く、個
体レベルでの感染経過の差異が他の疾病に類を見ないほ
ど大きい。超慢性感染症ともいえる本病の場合、子牛の
時に経口感染し、その後、一般には、平均3年〜6年以
上発病しない。中には10数年以上発病しない場合もあ
り、極端には一生発症しない場合もある。つまり、ヨー
ネ菌感染牛には、不顕性感染牛と発症牛があり、不顕性
感染牛には、抗体を有し、一定の病変を形成している無
症状牛と、ヨーネ菌に対する抗体反応や細胞性免疫が検
出しがたいキャリアー牛が存在する。[0003] Johne's disease is established when a calf is orally infected with Mycobacterium tuberculosis at an early stage after birth, but the process from infection to onset of Johne's disease is still largely unknown, and it is not possible at the individual level. Differences in the course of infection are unprecedented in other diseases. In the case of this disease, which can be said to be a super-chronic infectious disease, the disease is orally transmitted to a calf, and thereafter, the disease generally does not develop for an average of 3 to 6 years. In some cases, the disease does not develop for more than 10 years, and in extreme cases, it does not develop for life. In other words, cattle infected with S. tuberculosis include subclinically infected cattle and cattle that have developed the disease. There are carrier cows whose reaction and cellular immunity are difficult to detect.
【0004】この臨床症状や抗体の検出されない不顕性
感染牛(キャリアー牛)は、免疫学的診断(ELISA
法)では診断できない感染牛である。このキャリアー牛
は、特異的抗体レベルが診断限界以下でありながら、病
変を持ち、不規則な排歯があるため、防疫上極めて問題
になる。特に、ELISA法が免疫学的診断のスタンダ
ードとして世界中で用いられている現在、このELIS
A法による摘発が進んでくるため、感染レベルが低い牛
が残るようになる結果、ELISA法では摘発できない
キャリアー牛が相対的に増えているともいえる。[0004] Subclinically infected cattle (carrier cattle) in which these clinical symptoms and antibodies are not detected are subjected to immunological diagnosis (ELISA).
This is an infected cow that cannot be diagnosed under the law. Although the carrier cow has a specific antibody level below the diagnostic limit, it has lesions and irregular tooth removal, which is extremely problematic in epidemics. In particular, since the ELISA method is used worldwide as a standard for immunological diagnosis,
It can be said that the number of carrier cattle that cannot be detected by the ELISA method is relatively increasing as a result of the fact that the detection by the method A progresses and that the cows with low infection levels remain.
【0005】このキャリアー牛の不規則な排菌は、感染
の拡大に特に重要であり、糞便からのヨーネ菌を分離す
ることが、この時期に可能である唯一確実な診断法であ
る。しかし、この菌分離を使った診断も、その診断に必
要な量の菌の培養に数か月を費やさなけれはならないと
いう問題がある。[0005] Irregular evacuation of this carrier cow is particularly important for the spread of infection, and isolating J. bacillus from feces is the only reliable diagnostic method possible at this time. However, diagnosis using this bacterial isolation also has a problem that several months must be spent for culturing the amount of bacteria required for the diagnosis.
【0006】一般に、ヨーネ菌は、非定型抗酸菌III 群
に属し、通常、マイコバクチンを添加した培地上のみで
増殖する、特殊栄養要求性の細菌である。目に見えるコ
ロニー形成には7〜11週も要する超遅発育性の細菌で
あるため、それが、菌分離による診断法の推進を遅らせ
ている。近年、ヨーネ菌のDNAの持つ特異的挿入配列
IS900 の検出を行うには、ポリメラーゼチェーンリアク
ション(Polymerase chain reaction : PCR) により早期
鑑別することが可能になってきたが、糞便からのヨーネ
菌検出にはPCR 阻害物質の存在などにより菌分離より感
度が得られない場合がある。[0006] In general, S. tuberculosis belongs to the atypical mycobacterium group III and is a auxotrophic bacterium that usually grows only on a medium supplemented with mycobactin. It is a very slow-growing bacterium that can take as long as 7-11 weeks for visible colonization, which slows the progress of diagnostics by bacterial isolation. Recently, a specific insertion sequence possessed by the DNA of Mycobacterium tuberculosis
In order to detect IS900, it has become possible to perform early identification by polymerase chain reaction (PCR) .However, the detection of M. paratuberculosis from feces is more sensitive than bacterial isolation due to the presence of a PCR inhibitor. May not be obtained.
【0007】ヨーネ病の診断には、細菌分離、抗体検出
の他に、ヨーネ菌に対する宿主の細胞性免疫応答を検出
する方法がある。結核感染におけるツベルクリン反応と
同様の皮内反応が「ヨーニン反応」として用いられてい
るが、感染の比較的初期にのみ細胞性免疫応答が起き、
その後低下して検出できなくなるという、ヨーネ菌感染
における特異的な細胞性免疫応答の経過から、その応用
は感染後比較的初期に限られる。また、ヨーネ菌抗原を
認識したTリンパ球が再度の抗原暴露の際に反応・活性
化する際にインターフェロンガンマーを産生するという
現象を利用した、細胞性免疫検出キットも海外で販売さ
れていたが、現在は販売中止となっている。[0007] Diagnosis of Johne's disease includes methods of detecting a host's cellular immune response to Y. tuberculosis in addition to bacterial isolation and antibody detection. An intradermal reaction, similar to the tuberculin reaction in tuberculosis infection, is used as the "yonin response", but a cellular immune response occurs only relatively early in the infection,
Due to the course of the specific cellular immune response in Mycobacterium tuberculosis infection, which subsequently declines and becomes undetectable, its application is limited relatively early after infection. Cellular immunity detection kits that utilize the phenomenon that T lymphocytes recognizing M. paratuberculosis antigens produce interferon gamma when they react and activate upon re-exposure to antigens have also been sold overseas. , Is currently discontinued.
【0008】これまで、菌分離による診断法、特異抗体
の検出や細胞性免疫の検出、病理組織学的診断などによ
る診断がなされてきたが、これらの検査で捕まらない不
顕性感染個体に対してはこれまで十分な防疫および清浄
化が困難であった。このようにヨーネ病の発生機序は、
複雑で不明な点が多く、菌分離や免疫学的断法によって
も診断できない感染動物が存在するため、経済的被害は
極めて大きく且つ深刻である。しかし、本病の蔓延を妨
止するための病理・細菌・免疫学なとの研究が、現在着
実に進んでいることも確かであるが、現状では糞便中の
ヨーネ菌の有無を定期的に調べるか、感染牛の抗体が自
然に上昇するのを捕らえて免疫学的診断を行うというの
が現状のヨーネ病に対する診断の実状であるといえる。Hitherto, diagnosis has been made by isolation of bacteria, detection of specific antibodies, detection of cell-mediated immunity, and histopathological diagnosis. Up to now, it has been difficult to adequately prevent and clean the disease. Thus, the mechanism of Johne's disease
The economic damage is extremely large and serious because there are many infected animals that are complicated and unclear, and cannot be diagnosed by bacterial isolation or immunological method. However, studies on pathology, bacteria, and immunology to prevent the spread of this disease are certainly progressing steadily, but at present, the presence or absence of Y. bacillus in feces is regularly checked. It can be said that the current state of diagnosis for Johne's disease is to examine or catch the spontaneous rise of antibodies in infected cattle and make an immunological diagnosis.
【0009】ヨーネ病の感染から発症に至るまてのプロ
セスに関し、これまでに明らかにされている事項につい
て以下に述べる。ヨーネ病は、ヨーネ菌が腸管腔内に存
在するというだけでは菌増殖や宿主の病的被害は起こら
ない。ヨーネ歯はサルモネラ菌、シゲラ菌、ある種の大
腸菌およぴトレポネーマのような運動性や細胞侵襲性を
持たず、腸粘膜バリヤーをいかして突破するのかは長い
間不明であった。新生子牛の小腸吸収上皮細胞が初乳抗
体などの巨大分子をピノサイトーシス(飲作用)により
活発に取り込むことから、初乳やミルクとともに飲み込
まれたヨーネ菌も同様に取り込まれるであろうと推測が
なされていたが、その後それは事実でないことが明らか
にされた(Chiodini RJ, Van Kruiningen HJ, Merkal R
S、Ruminant paratuberculosis (Johne's disease): th
e current status andfuture prospects. Cornell Vet.
74(3):218-62 (1984)。Regarding the process from infection to onset of Johne's disease, matters that have been clarified so far will be described below. Johne's disease does not cause bacterial proliferation or pathological damage to the host merely by the presence of the yeast in the intestinal lumen. Johnet teeth do not have the motility and cell invasiveness of Salmonella, Shigella, certain Escherichia coli, and Treponema, and it has long been unknown how to break through the intestinal mucosal barrier. Since the intestinal absorptive epithelial cells of newborn calves actively take up macromolecules such as colostrum antibodies by pinocytosis (drinking action), it is speculated that Y. bacilli swallowed with colostrum and milk will be taken up as well. It was later revealed that this was not the case (Chiodini RJ, Van Kruiningen HJ, Merkal R
S, Ruminant paratuberculosis (Johne's disease): th
e current status andfuture prospects.Cornell Vet.
74 (3): 218-62 (1984).
【0010】本発明者らは、子牛の回腸ループを用いた
実験で、腸腔のヨーネ菌が腸腔のパイエル板のドーム部
を被う特珠なM細胞の貪食により受動的に上皮内に取り
込まれ、さらに、上皮内・上皮下マクロファージ(M
φ)によりさらにリンパ装置の目的部に運ばれることを
光学顕微鏡的および電子顕微鏡的に明らかにした〔百溪
英一、ヨーネ病の病理発生と防疫について、日本獣医師
会雑誌 42:229-237 (1992) 〕。この実験感染では、M
細胞以外の絨毛吸収上皮細胞や未分化クリプト上皮細
胞、胚細胞などによるヨーネ菌取り込みは認められなか
った。さらに、ヨーネ菌に対する抗体がヨーネ菌のパイ
エル板内侵入を促進する可能性を示唆することを、本発
明者はすでに明らかにしている。子牛にヨーネ菌が感染
する場合、母牛の糞便中に排出された菌が乳房などの体
表や環境に付着し、子牛が経口感染するが、不顕性感染
牛の乳房上リンパ節の27%、ミルク中に11.6% のヨーネ
菌が検出されることから、感染のある地域では糞便以外
にミルクや初乳中にもヨーネ菌が存在し、糞便やミルク
も重要な感染源となることが明らかにされた〔Sweeney
R, Whitlock R, and Rosenberger AE, Journal of Clin
ical Microbiology 30:166-171 (1992) 〕。In an experiment using a calf ileum loop, the present inventors passively enter the epithelium due to the phagocytosis of extraordinary M cells that infect the intestinal Peyer's patch dome in the intestinal cavity. And is further taken up by intraepithelial and subepithelial macrophages (M
(φ) revealed by light microscopy and electron microscopy that it was further transported to the target part of the lymphatic device [Eikichi Hyakukei, J. Veterinary Society, 42: 229-237 (1992)]. In this experimental infection, M
Uptake of Mycobacterium tuberculosis by villus-absorbing epithelial cells other than cells, undifferentiated crypt epithelial cells, and embryonic cells was not observed. Furthermore, the present inventors have already shown that an antibody against M. paratuberculosis suggests the possibility of promoting the invasion of M. paratuberculosis into Peyer's patches. When a calf is infected with Y. bacillus, the bacteria excreted in the feces of the mother cow attach to the body surface and environment, such as the udder, and the calf is infected orally. 27% of the bacteria and 11.6% of the bacterium are detected in milk, so that in the infected area, bacilli are present not only in feces but also in milk and colostrum, and feces and milk are also important sources of infection. [Sweeney
R, Whitlock R, and Rosenberger AE, Journal of Clin
ical Microbiology 30: 166-171 (1992)].
【0011】子牛の小腸の粘膜リンパ装置は、全小腸組
織の86%を占め、その1/3が上部小腸に、残り2/
3が回腸に分布しており、また、回腸パイエル板のドー
ム上皮は、M細胞のみの均一な構成細胞からなるが、小
腸上部に分布するリンパ装置のドームはM細胞と通常の
吸収上皮細胞の混在した状態で被われていることが知ら
れている〔Liebler E, Inaugural-Dessertation zur Er
largung des Grades eines Doctor Medicinae dir Tier
arzliche Hochshule Hannover(1985) 〕。したがって、
本発明者らの上記光学顕微鏡的・電子顕微鏡的観察結果
は、ヨーネ菌の侵入門戸(M細胞)は回腸により多く準
備されていることを示しており、ヨーネ病の初期感染病
変が回腸下部に形成されやすい理由を説明するものであ
るといえる。The calf small intestinal mucosal lymph device accounts for 86% of the total small intestine tissue, one third of which is in the upper small intestine and the remaining 2 /
No. 3 is distributed in the ileum, and the dome epithelium of the ileal Peyer's patch consists of uniform constituent cells consisting of only M cells, while the dome of the lymphatic device distributed in the upper part of the small intestine is composed of M cells and normal absorptive epithelial cells. It is known that they are covered in a mixed state (Liebler E, Inaugural-Dessertation zur Er
largung des Grades eines Doctor Medicinae dir Tier
arzliche Hochshule Hannover (1985)]. Therefore,
The light microscopic / electron microscopic observations of the present inventors show that the invasion gate (M cells) of M. paratuberculosis is prepared more in the ileum, and the initial infection lesion of Johne's disease is located in the lower ileum. It can be said that it explains the reason why it is easily formed.
【0012】M細胞は、腸管腔内に存在する腸内細菌を
無制限、無差別に取り込むのではなく、そこには選択的
取り込み機構があるとされており、Vibrio cholerae で
は生菌のみがウサギの腸のM細胞に取り込まれていると
いうが、ヨーネ菌の場合は生菌、死菌ともに取り込まれ
ており、その選択機構は単純なものではない〔百溪英
一、ヨーネ病の病理発生と防疫について、日本獣医師会
雑誌 42:229-237 (1992) 〕。腸は、栄養物としては多
種類の食事性抗原の取り込みを余儀なくされる組織であ
るが、無駄なあるいは過剰な免疫反応(食物アレルギー
等)を起こさないように危険性のない食餌性抗原と病原
性微生物抗原を区別する機構を持っており、これにはT
リンパ球が関与している。M cells do not take up intestinal bacteria present in the intestinal lumen indefinitely and indiscriminately, but it is said that they have a selective uptake mechanism. In Vibrio cholerae, only viable bacteria are derived from rabbits. It is said that it is taken up by intestinal M cells, but in the case of Bacillus subtilis, both live and dead bacteria are taken up, and the selection mechanism is not simple [Eikichi Hyakkei, Pathogenesis and prevention of Johne's disease Journal of the Japan Veterinary Medical Association, 42: 229-237 (1992)]. The intestine is a tissue that is required to take up many types of dietary antigens as nutrients, but there are no dangerous dietary antigens and pathogens that do not cause unnecessary or excessive immune reactions (such as food allergies). It has a mechanism for distinguishing bacterium antigens, including T
Lymphocytes are involved.
【0013】M細胞は、ペルオキシダーゼなどの巨大分
子や種類によるが、細菌をも取り込むことが証明されて
いる。またクラミジアspや数種類のウイルスがM細胞に
感染することが知られており、次第に腸管腔内の抗原の
サンプリングおよびその輸送という生体防御機能と同時
に特定の感染ルートとしての意義も明らかにされてきて
いる。しかし、これまで、M細胞の機能や役割について
現在までに明らかにされている部分は僅かであった〔Ow
en RL 、Uptake and transport of intestinal macromo
lecules and microorganisms by M cells in Peyer's p
atches--a personal and historical perspective.Semi
n Immunol 11:157-63 (1999)〕。この機能の解明が進む
とM細胞によるヨーネ菌の取り込み阻止というような形
の感染予防が可能になることを、本発明者らはすでに明
らかにしている〔百溪英一、ヨーネ病の病理発生と防疫
について、日本獣医師会雑誌 42:229-237 (1992) 〕。M cells, depending on macromolecules and types such as peroxidase, have been proven to take up bacteria. It is also known that Chlamydia sp and several kinds of viruses infect M cells, and the significance as a specific infection route has been elucidated as well as the biological defense function of antigen sampling and transport in the intestinal lumen. I have. However, to date, only a small portion has been revealed about the functions and roles of M cells [Ow
en RL, Uptake and transport of intestinal macromo
lecules and microorganisms by M cells in Peyer's p
atches--a personal and historical perspective.Semi
n Immunol 11: 157-63 (1999)]. The present inventors have already shown that if this function is elucidated, it will be possible to prevent infection in the form of inhibiting the uptake of M. paratuberculosis by M cells [Eikichi Hyakkei, pathogenesis of Johne's disease] And Japanese Journal of Veterinary Medicine 42: 229-237 (1992)].
【0014】ところで、感染後、平均3年〜6年以上発
病しないこの潜伏期間中においては、ヨーネ菌は腸粘膜
腸管膜リンパ節のマクロファージ(Mφ)に静止状態で
存在しており、不顕性感染状態にあると考えられる実験
感染子牛組織の病変は、非常に少数のMφ系細胞からな
り、極めて少数の菌しか見られず、組織切片上に菌が証
明できない場合が多い。この潜伏期に病変から発症期へ
の引き金となるのは、下痢症状や大量の排歯(糞便1g中
に10〜100万個)に先駆けて、静止状態の病変内で
の菌の増殖亢進と、それにそれに伴う細胞外への菌や菌
抗原の放出が起こると考えられる。[0014] By the way, during the incubation period in which the disease does not develop for an average of 3 to 6 years after the infection, M. paratuberculosis is present in the macrophages (Mφ) of the intestinal mucosal mesenteric lymph nodes in a quiescent state. The lesion of the experimentally infected calf tissue considered to be in an infected state is composed of a very small number of Mφ-type cells, shows only a very small number of bacteria, and often cannot prove the bacteria on the tissue section. In this incubation period, the trigger from the lesion to the onset period is that, in advance of diarrhea symptoms and a large amount of tooth removal (100 to 1 million per 1 g of stool), the proliferation of bacteria within the quiescent lesion, It is thought that the release of bacteria and fungal antigens out of the cells occurs accordingly.
【0015】その結果、Mφが病変に集合・定着し、肉
芽腫の形成・拡大が起こり、同時に液性の免疫応答も高
まる。Mφ内で潜伏しているヨーネ菌の増殖を亢進させ
る機構については、ヨーネ菌がマイコバクチン依存性
で、増殖・代謝に必須の鉄獲得能が極めて弱く特殊であ
る点から、細胞内でも当然、鉄の有無・鉄イオン濃度に
左右されるわけで、組織細胞内の鉄や鉄結合性蛋白と菌
増殖の関係は重要視される〔Momotani E, Immunohistoc
hemical distribution ofyferritin, lactoferrin, and
transferrin ingranulomas of bovine paratuberculos
is. Infect Immun. 52:623-627 (1986).;百溪英一、ヨ
ーネ病の病理発生機構の研究、農林水産省家畜衛生試験
場研究報告、96:275-280 (1991) 〕。As a result, Mφ aggregates and colonizes the lesion, and granuloma is formed and expanded, and at the same time, the humoral immune response is increased. Regarding the mechanism that enhances the growth of M. paratuberculosis latent in Mφ, the fact that M. paratuberculosis is mycobactin-dependent and has a very weak and special ability to acquire iron essential for growth and metabolism. The relationship between iron and iron-binding protein in tissue cells and bacterial growth is important because it depends on the presence or absence and iron ion concentration (Momotani E, Immunohistoc
chemical distribution ofyferritin, lactoferrin, and
transferrin ingranulomas of bovine paratuberculos
Infect Immun. 52: 623-627 (1986) .; Eiichi Hyakkei, Study on the Pathogenesis of Johne's Disease, Research Report on Livestock Hygiene Laboratory, Ministry of Agriculture, Forestry and Fisheries, 96: 275-280 (1991)].
【0016】この潜伏しているヨーネ菌の増殖を亢進さ
せる機構については、次のように推測される。急性感染
や実験的にLPS、結核菌細胞壁を接種すると、敗血症
防止のための非特異的生体防御反応である低鉄血症が起
こり、その後トランスフェリン(Tf)に結合している
血清鉄は、ラクトフェリン(Lf)の介在でMφ内へ移
動し、Mφ内の鉄濃度は高まり、ヨーネ菌増殖が促進さ
れる。宿主が細菌増殖に必須の鉄を菌に利用されないよ
うに、血中からMφ内に隠したところ、その隠し場所に
ヨーネ菌が待っていたという皮肉な現象である。The mechanism that enhances the growth of the latent Mycobacterium tuberculosis is presumed as follows. When acute infection or experimental inoculation of LPS or Mycobacterium tuberculosis cell wall results in hypoironemia, a non-specific host defense reaction to prevent sepsis, serum iron bound to transferrin (Tf) is then converted to lactoferrin ( Lf) intervenes and moves into Mφ, the iron concentration in Mφ increases, and the growth of M. paratuberculosis is promoted. It is an ironic phenomenon that when the host hid in the Mφ from the blood so that the iron which is indispensable for bacterial growth is not used by the bacterium, the fungus was waiting in the hiding place.
【0017】これは、(i).抗酸菌の産生する2種類
の鉄キレート(脂溶性のマイコバクチンと水溶性のエキ
ソケリン)は、宿主の鉄結合性蛋白{フェリチン(F
t)、TfおよびLf}から鉄を奪い、菌に供給するこ
とがinvitro で証明されていること、(ii).免疫組
織学的にヨーネ病肉芽腫にはこれら鉄結合性蛋白が局在
していること、(iii).マイコパクチンの存在しな
いpHの低い状態では、TfとLfから遊離した鉄を利
用してヨーネ菌が増殖することがラジオメトリック法で
証明されていること、(iv). 肉芽腫を構成する類上皮
細胞は、活性化・分化したMφであり、活性化Mの結合
鉄取り込みはMφに比べて有意に高いことが知られてい
ること、を根拠としている( 百溪英一、ヨーネ病の病理
発生機構の研究、農林水産省家畜衛生試験場研究報告、
96:275-280 (1991) 。This means that (i). The two types of iron chelates (liposoluble mycobactin and water-soluble exochelin) produced by acid-fast bacilli are compatible with the host iron-binding protein {ferritin (F).
t) demonstrating in vitro that it deprives Tf and Lf 鉄 of iron and supplies it to the fungus; (ii). Immunohistologically that these iron-binding proteins are localized in Johne's disease granuloma, (iii). It has been proved by a radiometric method that Mycobacterium tuberculosis grows using iron released from Tf and Lf in a low pH state where mycopactin does not exist. (Iv). Epithelioid cells constituting granuloma Is activated and differentiated Mφ, and it is known that the activated iron uptake of activated M is known to be significantly higher than that of Mφ (Eikichi Hyakukei, Pathogenesis mechanism of Johne's disease) Research, Ministry of Agriculture, Forestry and Fisheries Livestock Hygiene Laboratory
96: 275-280 (1991).
【0018】このように、ヨーネ病の感染から発症に至
るまでの病理発生機序についてはかなり明らかにされて
きているものの、腸管膜リンパ節Mφにヨーネ菌が静止
状態で存在する間に、ヨーネ菌を排除するための治療法
は、現在、実用化レベルまでに至ってないし、我が国で
はヨーネ病は家畜法定伝染病に指定されているため抗生
物質などによる治療は行わない。実験的報告はあるもの
の、治療停止後に再発し、また肉やミルク中への抗生物
質移行の問題があり実用的ではない(St-Jean G, Jernig
an AD 、Treatment of Mycobacterium paratuberculosi
s infection in ruminants. Vet Clin North AmFood An
im Pract.,7:793-804,(1991))。また、これまでに本感
染を予防する決定的な技術も開発されておらず、単に排
菌する母牛やその汚染環境から新生動物を隔離したり、
汚染環境の殺菌消毒など一般的な感染病の予防方法を施
すという程度に過ぎなかった。As described above, although the pathogenesis mechanism from the infection to the onset of Johne's disease has been considerably clarified, while Johne bacillus is present in the mesenteric lymph node Mφ in a quiescent state, Johne's disease occurs. Therapeutic methods for eliminating bacteria have not yet reached the level of practical use. In Japan, Johne's disease is designated as a domestic animal statutory infectious disease, so treatment with antibiotics is not performed. Although experimental reports have been reported, recurrence occurs after treatment has stopped, and antibiotic transfer into meat and milk is not practical (St-Jean G, Jernig
an AD, Treatment of Mycobacterium paratuberculosi
s infection in ruminants.Vet Clin North AmFood An
im Pract., 7: 793-804, (1991)). In addition, no definitive technology to prevent this infection has been developed so far, simply isolating newborn animals from the shedding cow and its contaminated environment,
It was only a matter of taking common preventive measures against infectious diseases, such as disinfecting the contaminated environment.
【0019】従来、ヨーネ病に対する具体的な対策とし
ては、ヨーネ菌死菌をオイルアシュパンドとともに皮下
などに打つワクチン接種がなされており効果があるとい
う報告等がある(van Schaik G, Kalis CH, Benedictus
G, Dijkhuizen AA, HuirneRB、Cost-benefit analysis
of vaccination against paratuberculosis in dairy
cattle. Vet Rec 139:624-7(1996)、Molina JM, Anguia
no A, Ferrer O 、Study on immune response of goats
vaccinated with a live strain of Mycobacterium pa
ratuberculosis. Comp Immunol Microbiol Infect Dis
19:9-15(1996))。しかし、これらの方法は感染後の細胞
性免疫を高めるものの、感染防御効果はなく、発症率を
低下させるのみである。そのため、糞便から排菌を続け
る不顕性感染牛を生じ、根本的な問題解決が図れないば
かりか、汚染を拡大してしまうという問題がある。Conventionally, as a specific countermeasure against Johne's disease, there is a report that vaccination in which killed Johnella bacillus is killed subcutaneously with oil ashpand has been effective (van Schaik G, Kalis CH, Benedictus
G, Dijkhuizen AA, HuirneRB, Cost-benefit analysis
of vaccination against paratuberculosis in dairy
cattle.Vet Rec 139: 624-7 (1996), Molina JM, Anguia
no A, Ferrer O, Study on immune response of goats
vaccinated with a live strain of Mycobacterium pa
ratuberculosis.Comp Immunol Microbiol Infect Dis
19: 9-15 (1996)). However, although these methods enhance cellular immunity after infection, they have no protective effect on infection and only reduce the incidence. As a result, subclinical infected cows that continue to shed bacteria from the feces are generated, and there is a problem that not only the fundamental problem cannot be solved but also the contamination is expanded.
【0020】ヨーネ病に対する経口ワクチンはヨーネ病
の研究の歴史上一度だけ試されており、病原性のないと
されるヨーネ菌株の生菌を成羊に経口投与し、その後ヨ
ーネ菌感染を行っている。この経口ワクチンでは感染防
御効果が得られなかったという報告されている(Gilmou
r NL, Absense of immunogenicity of an oral vaccine
against Mycobacterium paratuberculosis in sheep,
J Comp Pathol 83:437-445 (1973) 。この実験では非病
原性でマイコバクチン非依存性のヨーネ菌株とされた31
6F株が用いられたが、その後の報告では316F株はヨーネ
菌とは異なった菌株であることが報告されている〔Thor
el MF, Krichevsky M, Levy-Frebault VV, Numericalta
xonomy of mycobactin-dependent mycobacteria, emend
ed description of Mycobacterium avium, and descrip
tion of Mycobacterium avium subsp. aviumsubsp. no
v., Mycobacterium avium subsp. paratuberculosis su
bsp. nov., and Mycobacterium avium subsp. silvatic
um subsp. nov. Int J Syst Bacteriol40:254-60(199
0); Ohene-Gyan KA, Haagsma J, Davies MJ, Hounsel
l EF、Novel glycolipids of Mycobacterium avium and
related M. paratuberculosis strains of relevance
to AIDS an Crohn's disease. Comp Immunol Microbio
lInfect Dis 18:161-70 (1995) 〕。An oral vaccine against Johne's disease has been tried only once in the history of Johne's disease research, and a live bacterium of a non-pathogenic Johne's strain is orally administered to an adult sheep and subsequently infected with Johne bacillus. I have. It was reported that this oral vaccine did not provide protection against infection (Gilmou
r NL, Absense of immunogenicity of an oral vaccine
against Mycobacterium paratuberculosis in sheep,
J Comp Pathol 83: 437-445 (1973). In this experiment, a non-pathogenic, mycobactin-independent Yone strain was identified.31
The 6F strain was used, but subsequent reports have reported that the 316F strain is a different strain from M. paratuberculosis [Thor
el MF, Krichevsky M, Levy-Frebault VV, Numericalta
xonomy of mycobactin-dependent mycobacteria, emend
ed description of Mycobacterium avium, and descrip
tion of Mycobacterium avium subsp.
v., Mycobacterium avium subsp.paratuberculosis su
bsp.nov., and Mycobacterium avium subsp.silvatic
um subsp.nov.Int J Syst Bacteriol40: 254-60 (199
0); Ohene-Gyan KA, Haagsma J, Davies MJ, Hounsel
l EF, Novel glycolipids of Mycobacterium avium and
related M. paratuberculosis strains of relevance
to AIDS an Crohn's disease.Comp Immunol Microbio
lInfect Dis 18: 161-70 (1995)].
【0021】M細胞に関わる免疫についての特許につい
ては、例えば宿主のパイエル板細胞等のIgAの産生部
位を刺激し、IgA産生活性を促進させてその産生量を
増加させ、感染予防やアレルギー反応を阻止するするた
めに、ビフィドバクテリウム属菌のプロトプラストまた
は細胞質膜を経口投与する技術(特開平4−34253
3号公報)、経口投与後効率的に消化管内パイエル板に
薬剤を送運させるために、リポソーム、エマルジョン、
または水溶性ミセル等の経口投与用脂質まく構造体の膜
成分にホスファチジルセリン、マンノース誘導体、マン
ナン誘導体などの特定の物質を含有させる技術(特開平
5−17344号公報)、同じくパイエル板への生理活
性物質を効率的に移行させるために、ホスファチジルコ
リン、コレストロールおよびホスファチジルイノシトー
ルを脂質成分として含有するリポソームと該リポソーム
に封入される生理活性物質とを含有してなる製剤を経口
投与する技術(特許第2814307号)等があるが、
ヨーネ病の感染防御に特異抗体が全く無効であるという
特徴からも、これらがヨーネ病の防止、治療について特
に示唆するものではない。Patents relating to immunity involving M cells include, for example, stimulating IgA production sites such as host Peyer's patch cells, promoting IgA production activity, increasing the amount of IgA production, and preventing infection and allergic reactions. For preventing oral infections by orally administering protoplasts or cytoplasmic membranes of Bifidobacterium (Japanese Patent Application Laid-Open No. 4-34253).
No. 3), liposomes, emulsions, and the like in order to efficiently transport drugs to the Peyer's patch in the digestive tract after oral administration.
Alternatively, a technique of including a specific substance such as phosphatidylserine, a mannose derivative, or a mannan derivative in a membrane component of a lipid-spreading structure for oral administration such as a water-soluble micelle (Japanese Patent Laid-Open No. 5-17344). In order to efficiently transfer an active substance, a technique for orally administering a preparation containing a liposome containing phosphatidylcholine, cholesterol and phosphatidylinositol as a lipid component and a physiologically active substance encapsulated in the liposome (Japanese Patent No. 2814307) No.) etc.
The fact that specific antibodies are completely ineffective at protecting Johne's disease from infection does not particularly suggest prevention or treatment of Johne's disease.
【0022】また、因果関係は明確にされてはいない
が、近年、人のクローン病(厚生省指定難病)の原因と
してヨーネ菌の関与の可能性がクローズアップされてき
ており、家畜衛生、公衆衛生の立場からもヨーネ病に対
する抜本的な対策が急務とされており、早期のヨーネ病
予防方法や清浄化のための手段が求められている(Coll
ins MT、Mycobacterium paratuberculosis: a potentia
l food-borne pathogen?J Dairy Sci 80:3445-8 (199
7);Engstrand L 、Mycobacterium paratuberculosis a
nd Crohn's disease. Scand J Infect Dis Suppl 98:27
-9、1995))。Further, although the causal relationship has not been clarified, the possibility of the involvement of S. tuberculosis as a cause of human Crohn's disease (an intractable disease specified by the Ministry of Health and Welfare) has been increasing in recent years. From the standpoint of the government, drastic measures against Johne's disease are urgently needed, and there is a need for early Johne's disease prevention methods and means for cleaning (Coll)
ins MT, Mycobacterium paratuberculosis: a potentia
l food-borne pathogen? J Dairy Sci 80: 3445-8 (199
7); Engstrand L, Mycobacterium paratuberculosis a
nd Crohn's disease.Scand J Infect Dis Suppl 98:27
-9, 1995)).
【0023】[0023]
【発明が解決しようとする課題】本発明は、以上述べた
ヨーネ病に関する背景をもとになされたものである。す
なわち、本発明は、新生動物、特に子牛のヨーネ病感染
を予防するための方法およびヨーネ病感染予防ワクチン
を提供することを目的とする。これにより、ヨーネ病非
感染子牛を生育、生産し、ヨーネ菌感染のない清浄牛群
の確立を図るとともに、世界的に経済的損耗が問題にな
っているヨーネ病の対策に積極的な打開策を提供しよう
とするものである。SUMMARY OF THE INVENTION The present invention has been made based on the background concerning Johne's disease described above. That is, an object of the present invention is to provide a method for preventing Johne's disease infection in newborn animals, particularly calves, and a vaccine for preventing Johne's disease infection. This will allow the growth and production of calves without Johne's disease, establish a herd free of Johne-infected calves, and proactively address measures against Johne's disease, a problem of economic depletion worldwide. To provide a solution.
【0024】[0024]
【課題を解決するための手段】本発明者らは、新生子牛
の腸組織のパイエル板M 細胞が、ヨーネ菌の唯一の侵入
門戸であり、本細胞は腸管内の抗原情報を過剰に取り込
まない機構を有していることを先に明らかにしている
が、その後鋭意研究を重ねた結果、その取り込み制御機
構を人為的に誘導できるという知見、すなわち、新生動
物、特に新生子牛のパイエル板ドーム上皮のM細胞が、
ヨーネ菌の取り込みを持続的に行わない性質(貪食の抑
制制御)を、人為的な死菌の経口投与により誘導して、
ヨーネ菌生菌の特異的侵入門戸であるM細胞からの受動
的侵入(取り込みによる侵入)を抑制することにより、
子牛のヨーネ病感染を予防することができることを見出
し、本発明を完成したものである。本発明の経口ワクチ
ンは、生後直ちに初乳ともにヨーネ菌死菌を投与すると
いう点から全く新しい方法であり、前記Gilmoure(1973)
の報告とは全く異なった考え方と仕組みに立脚した内容
のワクチンである。Means for Solving the Problems The present inventors have found that Peyer's patch M cells in the intestinal tissue of neonatal calves are the only entry gates for Bacillus subtilis, and these cells excessively take up antigen information in the intestinal tract. Although it has been clarified earlier that it has no mechanism, after extensive studies, it has been found that the uptake control mechanism can be artificially induced, that is, Peyer's patch of newborn animals, especially newborn calves M cells in the dome epithelium
Induced by the oral administration of artificially killed bacteria, the property that does not sustain the uptake of Mycobacterium tuberculosis (suppression of phagocytosis)
By suppressing the passive invasion (invasion by uptake) from M cells, which are the specific invasion gates of live Y. fungi,
The inventors have found that calf can be prevented from infection with Johne's disease, and have completed the present invention. The oral vaccine of the present invention is a completely new method in that the colostrum is administered with killed Mycobacterium tuberculosis immediately after birth, and the Gilmoure (1973)
It is a vaccine based on a completely different concept and mechanism from that of the report.
【0025】すなわち、本発明は、(1)、M細胞の取
り込み制御を誘導することにより牛の感染を予防する方
法に存する。そして、(2)、ヨーネ菌(Mycobacteriu
m avium subspecies paratuberculosis)を加熱により死
菌とし、死菌とした該ヨーネ菌を新生動物に経口投与し
てヨーネ菌の特異的侵入経路である腸粘膜のM細胞の取
り込み制御を誘導し、その後の生きたヨーネ菌の侵入を
阻害することからなるヨーネ病感染に対する予防方法に
存する。そしてまた、(3)、ヨーネ菌(Mycobacteriu
m avium subspecies paratuberculosis)を加熱により死
菌とし、死菌とした該ヨーネ菌を新生子牛に経口投与す
ることからなる牛のヨーネ病感染に対する予防方法に存
する。そしてまた、(4)、清浄な初乳とともにヨーネ
菌死菌を経口投与するヨーネ病感染に対する予防方法に
存する。そしてまた、(5)、ヨーネ菌(Mycobacteriu
m avium subspecies paratuberculosis)の加熱死菌を含
有することからなる新生子牛用ヨーネ病感染予防ワクチ
ンに存する。そしてまた、(6)、正常初乳にヨーネ菌
死菌を含有させてなるヨーネ病感染予防ワクチンに存す
る。That is, the present invention resides in (1) a method for preventing infection of cattle by inducing the control of M cell uptake. And (2) Mycobacteriu (Mycobacteriu)
m avium subspecies paratuberculosis) was killed by heating, and the killed S. tuberculosis was orally administered to a newborn animal to induce the uptake control of M cells in the intestinal mucosa, which is a specific invasion route of S. tuberculosis. The present invention relates to a method for preventing Johne's disease infection, which comprises inhibiting the invasion of living Mycobacterium tuberculosis. And (3), Mycobacteriu (Mycobacteriu)
mavium subspecies paratuberculosis) is killed by heating, and the killed S. tuberculosis is orally administered to neonatal calves. And (4) a method for preventing Johne's disease infection by orally administering killed S. tuberculosis along with clean colostrum. And (5), Mycobacteriu (Mycobacteriu)
mavium subspecies paratuberculosis). Also, (6) a vaccine for preventing infection with Johne's disease, comprising killed Mycobacterium tuberculosis in normal colostrum.
【0026】[0026]
【発明の実態の形態】本発明は、新生子牛の腸組織のパ
イエル板M細胞は、ヨーネ菌唯一の侵入門戸であり、こ
のM細胞は腸管内の抗原情報を過剰に取り込まない機構
を有し、その取り込み機構を人為的に誘導する、つま
り、新生子牛に加熱死菌を経口投与すると、M細胞はそ
の後の生きたヨーネ菌の侵入を阻害する、という事実を
適用してヨーネ病の予防を行うものである(図1参
照)。具体的には、一定量のヨーネ菌加熱死菌を、牛の
無菌的フリーズドライ初乳に混入して製剤として、適宜
温湯にて希釈し、分娩後、母牛から隔離した新生子牛に
数日間経口投与し、適宜投与機関および投与後のM細胞
によるヨーネ菌に対する取り込みを特異的に制御するも
のである。その際に、無菌的初乳とともに当該ワクチン
を与えることにより、子牛の免疫抵抗性の強化と母牛の
ミルクを介したヨーネ菌の感染を阻止することができ
る。DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the idea that Peyer's patch M cells in the intestinal tissue of neonatal calves are the only invasion gates of Mycobacterium tuberculosis, and these M cells have a mechanism that does not excessively take up antigen information in the intestinal tract. However, by applying the fact that the uptake mechanism is artificially induced, that is, when heat-killed bacteria are orally administered to neonatal calves, M cells inhibit the subsequent invasion of living M. tuberculosis by applying the fact that M. It is for prevention (see FIG. 1). Specifically, a certain amount of heat-killed Bacillus paratuberculosis is mixed with aseptic freeze-dried colostrum of cattle as a preparation, diluted as appropriate with warm water, and delivered to newborn calves isolated from the mother after calving. It is orally administered for a day, and specifically controls uptake of M. tuberculosis by M cells after administration as appropriate. At this time, by giving the vaccine together with aseptic colostrum, it is possible to enhance the immune resistance of calves and prevent infection of Yeast bacteria via mother's milk.
【0027】[0027]
【実施例】本発明のワクチンの製造およびその適用は、
次ぎの(1)〜(5)の過程を経て行われる。 (1)ヨーネ菌(Mycobacterium avium subspecies par
atuberculosis )の培養 M. avium subspecies paratuberculosis (ATCC 10698
株) をマイコバクチンPを2mg/L(Allied Laboratories,
INC, Fayette, Mo, USA) 添加したMiddlebrook7H9 液体
培地(DIFCO、USA)で10日間培養した。培養には細胞培養
用フラスコ(800ml 容量、スミロンMS-20800)を用い、
培地の深さは1-2cm で37℃静置で行う。105 cfu/mlのヨ
ーネ菌から10日間培養で108 CFU/ml菌を得る。培養菌液
は50mlTPX 製遠心管(スミロンMS-57150) に分注し、20
00Gにて遠心し、菌のペレットを得る。これに0.01%の
0.01Mの無菌PBS を加え、再度懸濁し遠心洗浄を行う。 (2)経口投与死菌製造 72℃20分間加熱し、冷却後、凍結するかまたは凍結乾燥
してを保存する。 (3)無菌処理初乳と混合 無菌的初乳ないし45℃に加熱した温湯に乾燥初乳(日本
農産工業製マザーミルク等)を300g/900mlとなるように
混入し、ヨーネ菌死菌を5×1010個/900ml初乳となるよ
うに加えて調整する。 (4)分娩後新生子牛に経口投与 子牛は分娩後直ちに母牛から隔離して、清浄な環境下に
おき、分娩後30分以内にストマックチューブにてヨーネ
菌死菌入り初乳を900ml/30〜40kg/ 頭、投与する。12
時間以内に同量を投与する。翌日は初乳濃度を(3)の
1/2 に低下させたものを一日に2回、同量だけ投与す
る。 (5)(4)の処理後は無菌乾燥初乳ないし人工乳で隔
離保育する。EXAMPLES The production of the vaccine of the present invention and its application are as follows:
It is performed through the following steps (1) to (5). (1) Mycobacterium avium subspecies par
culture of M. avium subspecies paratuberculosis (ATCC 10698)
2mg / L (Allied Laboratories, Inc.)
INC, Fayette, Mo, USA) for 10 days in a Middlebrook 7H9 liquid medium (DIFCO, USA). Use a cell culture flask (800 ml capacity, Sumilon MS-20800) for culture.
Perform the culture at a depth of 1-2 cm at 37 ° C. 10 8 CFU / ml bacteria are obtained from 10 5 cfu / ml Mycobacterium tuberculosis by culturing for 10 days. The culture solution is dispensed into 50 ml TPX centrifuge tubes (Sumilon MS-57150), and
Centrifuge at 00G to obtain a bacterial pellet. 0.01% of this
Add 0.01M sterile PBS, resuspend and centrifuge. (2) Preparation of killed bacteria for oral administration Heat at 72 ° C for 20 minutes, cool and freeze or freeze-dry and store. (3) Mix with aseptic colostrum Aseptic colostrum or dried colostrum (mother milk manufactured by Nippon Nosan Kogyo Co., Ltd.) is mixed in hot water heated to 45 ° C. to a concentration of 300 g / 900 ml. Add and adjust so that it becomes × 1010 / 900ml colostrum. (4) Oral administration to newborn calves after parturition Calves are isolated from their mothers immediately after parturition and placed in a clean environment, and within 30 minutes after parturition, 900 ml of colostrum containing killed Yone bacteria is delivered in a stomach tube. / 30 to 40kg / head, given. 12
Administer the same amount within hours. The next day, the colostrum concentration was adjusted to (3)
The same amount is administered twice a day, reduced to half. (5) After the treatment of (4), isolate and raise with sterile dried colostrum or artificial milk.
【0028】[0028]
【実験1】子牛M細胞のヨーネ菌取り込みと、連続取り
込み抑制の確認; 〔実験方法〕 :生後1〜3日齢のホルスタイン種子牛9頭(初乳未摂
取子牛)を全身麻酔下で横臥させ、外科的開腹手術によ
り回腸末端部に2重結紮による回腸ループを複数作成
し、ヨーネ菌生菌ないしは死菌浮遊液を注入し、接種
後、15、30、60分後に全身麻酔下で腸組織を取り
出しホルマリン固定パラフィン包埋を実施し、4 μm の
組織標本を作製し、ヘマトキシリンエオジン染色および
チールネルゼン染色を行い光学顕微鏡による観察を行っ
た。さらに同様の実験を8頭の初乳未摂取子牛を用いて
行い、ヨーネ菌生菌ないしは死菌浮遊液注入後6時間な
いし20時間目に再度、全身麻酔下で腸組織を取り出しホ
ルマリン固定パラフィン包埋を実施し、4μm の組織標
本を作製し、ヘマトキシリンエオジン染色およびチール
ネルゼン染色を行い光学顕微鏡による観察を行った。[Experiment 1] Confirmation of uptake of Mycobacterium tuberculosis and suppression of continuous uptake of M. parasites by calf M cells Lay it down, make multiple ileal loops by double ligation at the distal end of the ileum by surgical laparotomy, inject a viable or dead bacterial suspension of Mycobacterium tuberculosis, and 15, 15, 60 minutes after inoculation, under general anesthesia. The intestinal tissue was taken out, embedded in formalin-fixed paraffin, a 4 μm tissue specimen was prepared, stained with hematoxylin-eosin and Thiel-Nelsen, and observed with an optical microscope. Further, the same experiment was carried out using eight colostrum-uninfected calves, and the intestinal tissue was removed again under general anesthesia 6 to 20 hours after the injection of the viable or dead bacterial suspension of the Y. fungus, formalin-fixed paraffin. Embedding was performed, a 4 μm tissue specimen was prepared, stained with hematoxylin-eosin and Thiel-Nelsen, and observed with an optical microscope.
【0029】〔実験結果〕接種後15、30、60分の
回腸パイエル板内にヨーネ菌の侵入は認められなかっ
た。しかし、接種後6〜20時間の回腸組織には腸管腔
内に様々な数のヨーネ菌が観察された。回腸組織内では
ヨーネ菌はパイエル板内に限られた数の生菌や死菌が観
察されたが、その前後の時間にはほとんど観察されなか
った。腸管腔内には多数のヨーネ菌が存在するにもかか
わらず、パイエル板に取り込まれた菌数は一般に非常に
少数であり、全く菌が認められない例もあった。これら
の実験から、ヨーネ菌の生菌や死菌の粘膜内取り込み
は、M細胞の取り込みにより成立するものであるが、ヨ
ーネ菌の持続的取り込みは起こらないことが示された。
少なくともヨーネ菌については生菌や死菌に対するM細
胞の取り込みに関する制御機構が存在することが明らか
にされた。この実験から、十分な量の死菌を分娩直後に
経口投与すると、一定のM細胞によるヨーネ菌死菌取り
込み後に生菌の取り込みが阻害される可能性が示された
(図2参照)。[Experimental Results] No invasion of Mycobacterium tuberculosis was observed in the ileal Peyer's patch at 15, 30, and 60 minutes after inoculation. However, various numbers of M. paratuberculosis were observed in the intestinal lumen of the ileum tissue 6-20 hours after inoculation. In the ileal tissue, a limited number of viable and dead bacteria was observed in the Peyer's patch in the ileal tissue, but was scarcely observed before and after that. Despite the presence of a large number of Mycobacterium tuberculosis in the intestinal lumen, the number of bacteria taken into Peyer's patches is generally very small, and in some cases, no bacteria are found. From these experiments, it was shown that uptake of live and dead bacteria of M. paratuberculosis into the mucous membrane was established by uptake of M cells, but continuous uptake of M. paratuberculosis did not occur.
It has been clarified that there is at least a control mechanism for the uptake of M cells into living and dead bacteria of Mycobacterium tuberculosis. This experiment showed that if a sufficient amount of killed bacteria was orally administered immediately after parturition, the uptake of live bacteria could be inhibited after the uptake of killed S. tuberculosis by certain M cells (see FIG. 2).
【0030】[0030]
【実験2】〔実験方法〕マウスは経口的にヨーネ菌感染
を起こすことから、上記子牛の実験で得られたデータを
元に、マウスにヨーネ菌の生菌を一度〜連続投与して、
異なった経過時間でパイエル板内のヨーネ菌の病理学的
証明を行った。C57BL/6 マウス、雌、14週齢24頭にヨー
ネ菌(ATCC 10698 株) 生菌を2×107cf/0.5mlをPBS に
浮遊させ胃ゾンデにより1回のみ経口接種した。一方16
匹の同種マウスに同様に死菌を経口接種した。マウスは
接種後、0、4 、5 、6 、7 、21、22、23時間目
に死菌接種マウスは各3頭、死菌接種では各2頭をエー
テルによる過麻酔下で安楽死後、パイエル板の存在する
部位の腸管を全て採取し20%ホルマリン固定した。パ
ラフィン包埋組織標本を抗酸菌染色してヨーネ菌の局在
を観察した。[Experiment 2] [Experimental method] Mice cause oral infection with M. paratuberculosis. Based on the data obtained in the above calf experiments, mice were administered live mice of M. paratuberculosis once to continuously,
Pathological proof of Mycobacterium tuberculosis in Peyer's patches at different elapsed times was performed. 24 × 14 weeks old C57BL / 6 mice, females, 14 weeks old, were proliferated with 2 × 10 7 cf / 0.5 ml of live Yeast strain (ATCC 10698 strain) in PBS and orally inoculated only once with a gastric tube. While 16
Similarly, the same mice were orally inoculated with the killed bacteria. At 0,4,5,6,7,21,22,23 hours after inoculation, 3 mice were inoculated with killed mice, and 2 mice were killed under over anesthesia with ether. All intestinal tracts at the site where the plate was present were collected and fixed in 20% formalin. Paraffin-embedded tissue specimens were stained with acid-fast bacilli to observe the localization of Mycobacterium tuberculosis.
【0031】〔実験結果〕パイエル板内の生菌は4 時間
目および22時間目各一例に、死菌は7、21、22時間
目に少数認められた。腸管腔内には種々の数の抗酸菌が
認められた。この実験から、マウスに経口投与した場
合、ヨーネ菌生菌、死菌ともにマウスのパイエル板内に
取り込まれるが、菌数は限られていることが明らかにさ
れた(図3参照)。[Experimental Results] Viable bacteria in the Peyer's patch were observed in each case at 4 hours and 22 hours, and a few dead bacteria were observed at 7, 21, and 22 hours. Various numbers of mycobacteria were found in the intestinal lumen. From this experiment, it was clarified that when administered orally to mice, both live and dead Staphylococcus paratuberculosis were taken up in the Peyer's patch of mice, but the number of bacteria was limited (see FIG. 3).
【0032】[0032]
【実験3】〔実験方法〕マウスに経口投与されたヨーネ
菌が常に腸管内に存在する場合にパイエル板への取り込
みが持続的に起こるのかどうかをヨーネ菌死菌を用いて
行った。実験方法:実験2と同様のマウスにヨーネ菌死
菌浮遊液を1時間間隔で3回にわたり胃ゾンデで接種し
た。その後、0、2 、3 、4 、5 、6 、7 時間目にパイ
エル板の存在する腸管部位を採取し、病理組織学的にヨ
ーネ菌の局在を観察した。[Experiment 3] [Experimental method] It was examined whether or not the uptake into the Peyer's patch occurs continuously when the M. tuberculosis orally administered to the mouse is always present in the intestinal tract, using killed M. tuberculosis. Experimental method: The same mice as in Experiment 2 were inoculated three times at 1 hour intervals with a gastric tube with killed S. tuberculosis suspension. Thereafter, at 0, 2, 3, 4, 5, 6, and 7 hours, the intestinal tract site where the Peyer's patch was present was collected, and the localization of S. tuberculosis was observed histopathologically.
【0033】〔実験結果〕5時間目の1症例にヨーネ菌
が観察されたのみで、他の症例には組織内のヨーネ菌は
認められなかった。腸管腔内には種々の数の抗酸菌が証
明された。この実験から、腸管腔内に常にヨーネ菌が存
在する状態においても、同じ腸管部位に存在するパイエ
ル板の中に、ヨーネ菌が常に観察されないことが確認さ
れた。この所見は、パイエル板に隣接して多くのヨーネ
菌が存在していても、パイエル板のM細胞はこれを継続
的に取り込んでいないことを意味している(図4参
照)。[Experimental Results] Only one B. fungus was observed in one case at 5 hours, and no B. fungi in the tissue was observed in the other cases. Various numbers of mycobacteria have been demonstrated in the intestinal lumen. From this experiment, it was confirmed that even in a state in which the fungus is always present in the intestinal lumen, the fungus is not always observed in the Peyer's patch present in the same intestinal tract site. This finding implies that even if a large number of M. tuberculosis is present adjacent to the Peyer's patch, the M cells of the Peyer's patch do not continuously take up this (see FIG. 4).
【0034】[0034]
【実験4】牛同様のヨーネ病に感染発症するヤギの回腸
ループ系を用いて、M-cellワクチンの効果を確認した。 〔実験方法〕シバヤギ3頭を用い、2頭を出生直後から
隔離し、2 日目まで、ヨーネ菌死菌を混入した牛初乳ド
ライミルク(M細胞ワクチン)を投与した。その後は母
山羊のもとにもどし、母乳と通常の人工乳を与えながら
保育し、生後20日目に全身麻酔下で、前述同様に回腸末
端部にループを形成し、ヨーネ菌 (ATCC 10698株) 生菌
を109 cfu/mlをループ内に接種した。接種後6時間お
よび20時間目に再度全身麻酔下で外科的にループを摘出
し、病理組織学的にヨーネ菌の局在について観察を行っ
た。本ワクチン非投与対照には同日齢の通常飼育された
子山羊を用いて20時間目の観察を行った。[Experiment 4] The effect of the M-cell vaccine was confirmed using a ileal loop system of a goat that develops infection with Johne's disease as in cattle. [Experimental method] Three Shiba goats were quarantined immediately after birth, and until day 2, bovine colostrum dry milk (M-cell vaccine) mixed with killed Mycobacterium tuberculosis was administered. After that, return to the mother's goat, raise it while feeding with mother's milk and normal artificial milk, and under general anesthesia on the 20th day after birth, form a loop at the end of the ileum as described above, ) 10 9 cfu / ml of live bacteria was inoculated into the loop. At 6 hours and 20 hours after the inoculation, the loop was surgically excised again under general anesthesia, and histopathologically observed for localization of S. tuberculosis. As a control to which this vaccine was not administered, observation was performed at 20 hours using a normal-bred goat of the same age.
【0035】〔実験結果〕ワクチン非投与のシバヤギの
回腸ループのパイエル板ドーム組織内のマクロファージ
内にわずかの抗酸菌が観察された。しかし、ワクチン投
与をされたシバヤギのパイエル板上皮およびドーム組織
内にはヨーネ菌は観察されなかった。いずれの症例にお
いても、回腸ループの腸管腔内には著しく多数のヨーネ
菌が観察された。この実験から、生後直ちにヨーネ菌死
菌を初乳とともに接種されたシバヤギでは、ヨーネ菌の
侵入経路であるM細胞に富んだ回腸ループ内へのヨーネ
菌接種においても、M細胞によるヨーネ菌の取り込みが
抑制されていることが示された。この結果は牛などの他
の反芻動物のヨーネ病感染予防にも本ワクチンが適用で
きることを明らかである(図5参照)。[Experimental Results] A few mycobacteria were observed in the macrophages in the Peyer's patch dome tissue of the ileal loop of the non-vaccinated sheep goat. However, no bacilli were observed in Peyer's patch epithelium and dome tissues of vaccinated sheep goats. In each case, a remarkably large number of Mycobacterium tuberculosis was observed in the intestinal lumen of the ileal loop. From this experiment, it was found that in Shibayagi inoculated with killed S. tuberculosis with colostrum immediately after birth, M. cell uptake of S. tuberculosis by M cells even in the inoculation of S. tuberculosis into the ileal loop enriched in M cells, which is an invasion route of S. tuberculosis Was suppressed. This result clearly shows that the vaccine can be applied to prevent the infection of Johne's disease in other ruminants such as cattle (see FIG. 5).
【0036】[0036]
【発明の効果】分娩後直ちに子牛を母牛から隔離し、無
菌的な初乳と混合された本死菌ワクチンを与えることに
より、母乳由来のヨーネ菌ばかりでなく、環境由来のヨ
ーネ菌などが経口接種されたとしても、ヨーネ菌のM細
胞からの侵入を阻害することにより、ヨーネ菌の組織内
への侵入(感染の成立)を阻止することができる。その
結果、本発明のワクチンを用いた予防方法により、すで
にヨーネ病に汚染した地域であっても、ヨーネ病非感染
子牛を生育、生産し、ヨーネ菌感染のない清浄牛群の確
立を図ることが可能である。EFFECTS OF THE INVENTION Immediately after parturition, calves are isolated from mother cows, and the killed vaccine mixed with aseptic colostrum is given to the bacterium, so that not only yeasts derived from breast milk but also yeasts derived from the environment can be obtained. Even if is orally inoculated, the invasion of M. paratuberculosis into tissues (establishment of infection) can be prevented by inhibiting the invasion of M. paratuberculosis from M cells. As a result, by the preventive method using the vaccine of the present invention, even in an area that has already been contaminated with Johne's disease, grow and produce calves without Johne's disease, and establish a clean cow herd that is free of Johne's disease infection. It is possible.
【図1】図1は、ヨーネ菌の侵入門戸である、小腸パイ
エル板およびドーム部の図、ならびにヨーネ菌死菌によ
るM細胞の取り込み抑制機構を示す図である。BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a diagram of a Peyer's patch and a dome portion of a small intestine, which is an invasion gate of Mycobacterium tuberculosis, and a diagram showing a mechanism of suppressing M cell uptake by killed Mycobacterium tuberculosis.
【図2】図2は、実験1の結果を示す図である。FIG. 2 is a diagram showing the results of Experiment 1.
【図3】図3は、実験2の結果を示す図である。FIG. 3 is a diagram showing the results of Experiment 2.
【図4】図4は、実験3の結果を示す図である。FIG. 4 is a diagram showing the results of Experiment 3.
【図5】図5は、実験4の結果を示す図である。FIG. 5 is a diagram showing the results of Experiment 4.
─────────────────────────────────────────────────────
────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成12年6月1日(2000.6.1)[Submission date] June 1, 2000 (2006.1)
【手続補正1】[Procedure amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】発明の名称[Correction target item name] Name of invention
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【発明の名称】 M細胞取り込み制御によるヨーネ病
感染の予防方法およびそのワクチンTitle: Method for preventing Johne's disease infection by controlling M cell uptake and vaccine thereof
Claims (6)
より牛の感染を予防する方法。1. A method for preventing bovine infection by inducing the control of M cell uptake.
cies paratuberculosis)を加熱により死菌とし、死菌と
した該ヨーネ菌を新生動物に経口投与してヨーネ菌の特
異的侵入経路である腸粘膜のM細胞の取り込み制御を誘
導し、その後の生きたヨーネ菌の侵入を阻害することか
らなるヨーネ病感染に対する予防方法。2. Mycobacterium avium subspe
cies paratuberculosis) was killed by heating, and the killed S. paratuberculosis was orally administered to a newborn animal to induce the uptake of M cells in the intestinal mucosa, which is a specific invasion pathway of S. tuberculosis, and then lived. A method for preventing Johne's disease infection, which comprises inhibiting the invasion of Mycobacterium tuberculosis.
cies paratuberculosis)を加熱により死菌とし、死菌と
した該ヨーネ菌を新生子牛に経口投与することからなる
牛のヨーネ病感染に対する予防方法。3. A Mycobacterium avium subspe
cies paratuberculosis) by heating, and orally administering to the neonatal calf the Johnes bacillus that has been killed, to prevent Johne's disease infection in cattle.
投与することを特徴とする請求項2または3記載のヨー
ネ病感染に対する予防方法。4. The method for preventing Johne's disease infection according to claim 2 or 3, wherein killed S. tuberculosis is orally administered together with clean colostrum.
cies paratuberculosis)の加熱死菌を含有することから
なる新生子牛用ヨーネ病感染予防ワクチン。5. A Mycobacterium avium subspe
cies paratuberculosis), a vaccine for preventing Johne's disease infection for newborn calves, comprising a heat-killed bacterium of Cies paratuberculosis).
るヨーネ病感染予防ワクチン。6. A vaccine for preventing infection with Johne's disease, which comprises killed Mycobacterium tuberculosis in normal colostrum.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000163840A JP4627579B2 (en) | 2000-05-31 | 2000-05-31 | Prevention of Johne's disease infection by controlling M cell uptake |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000163840A JP4627579B2 (en) | 2000-05-31 | 2000-05-31 | Prevention of Johne's disease infection by controlling M cell uptake |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001342147A true JP2001342147A (en) | 2001-12-11 |
JP4627579B2 JP4627579B2 (en) | 2011-02-09 |
Family
ID=18667540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000163840A Expired - Fee Related JP4627579B2 (en) | 2000-05-31 | 2000-05-31 | Prevention of Johne's disease infection by controlling M cell uptake |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4627579B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003013596A1 (en) * | 2001-08-07 | 2003-02-20 | Massey University | Vaccine |
WO2003080082A1 (en) * | 2002-03-21 | 2003-10-02 | Anadis Ltd | Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment |
AU2003212098B2 (en) * | 2002-03-21 | 2008-07-24 | Anadis Ltd | Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03204820A (en) * | 1989-10-12 | 1991-09-06 | Nippon Saibai Suisan Kk | Preventive vaccine for bacterial disease of prawn and production thereof |
-
2000
- 2000-05-31 JP JP2000163840A patent/JP4627579B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03204820A (en) * | 1989-10-12 | 1991-09-06 | Nippon Saibai Suisan Kk | Preventive vaccine for bacterial disease of prawn and production thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003013596A1 (en) * | 2001-08-07 | 2003-02-20 | Massey University | Vaccine |
WO2003080082A1 (en) * | 2002-03-21 | 2003-10-02 | Anadis Ltd | Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment |
AU2003212098B2 (en) * | 2002-03-21 | 2008-07-24 | Anadis Ltd | Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment |
Also Published As
Publication number | Publication date |
---|---|
JP4627579B2 (en) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sweeney et al. | Streptococcus equi infections in horses: guidelines for treatment, control, and prevention of strangles | |
US8142760B2 (en) | Vaccination for Lawsonia intracellularis | |
EP1663302A2 (en) | Method for vaccination of poultry by bacteriophage lysate | |
Kwon et al. | Efficacy of oral immunization with Edwardsiella tarda ghosts against edwardsiellosis in olive flounder (Paralichthys olivaceus) | |
Denis et al. | Vaccines against bovine mastitis in the New Zealand context: What is the best way forward? | |
Hosseini et al. | Efficacy of inactivated variant porcine epidemic diarrhea virus vaccines in growing pigs | |
Josefsen et al. | Bacterial infections and diseases | |
Qureshi et al. | Partial protection against oral challenge with Mycobacterium bovis in ferrets (Mustela furo) following oral vaccination with BCG | |
Suzuki et al. | SS1 Helicobacter pylori disrupts the paracellular barrier of the gastric mucosa and leads to neutrophilic gastritis in mice | |
Merino-Contreras et al. | Mucosal immune response of spotted sand bass Paralabrax maculatofasciatus (Steindachner, 1868) orally immunised with an extracellular lectin of Aeromonas veronii | |
Macedo et al. | Effect of enrofloxacin on Haemophilus parasuis infection, disease and immune response | |
Rybarczyk et al. | Effects of lactoferrin treatment on Escherichia coli O157: H7 rectal colonization in cattle | |
Abd El-Moez et al. | Bacterial causes of sudden death in farm animals | |
JP4627579B2 (en) | Prevention of Johne's disease infection by controlling M cell uptake | |
Cross et al. | Systemic but not intra-intestinal vaccination with BCG reduces the severity of tuberculosis infection in ferrets (Mustela furo) | |
AU751517B2 (en) | TGC method for inducting targeted somatic transgenesis | |
US8647640B2 (en) | Vaccine compositions and methods of use to protect against infectious disease | |
Kotb et al. | Evaluation of using different adjuvants used for preparation of Staphylococcus aureus mastitis vaccine on the immune response | |
Kasa et al. | Review of common bacterial cause and management of neonatal calf diarrhea in cattle | |
Knop et al. | Protection against cholera: A bactericidal mechanism on the mucosal surface of the small intestine of mice | |
Nagaraja | Corynebacterium | |
Silva et al. | An outbreak of acute bovine mastitis caused by Klebsiella pneumoniae in a dairy herd | |
Singh et al. | Therapeutic management of Bovine Brucellosis in endemically infected dairy cattle herd of native Sahiwal breed. | |
Jacob | Filamentous bacteria: Actinomyces, Nocardia, Dermatophilus, and Streptobacillus | |
Daniels et al. | Miscellaneous Gram-Positive Bacterial Infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100304 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100430 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100604 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100906 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100906 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101006 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101105 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101108 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131119 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |